[{"address1": "630 5th Avenue", "address2": "20th Floor", "city": "New York", "state": "NY", "zip": "10111", "country": "United States", "phone": "844 689 3939", "website": "https://www.anavex.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.", "fullTimeEmployees": 40, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher U. Missling M.B.A., M.S., Ph.D.", "age": 57, "title": "President, CEO, Secretary & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 828253, "exercisedValue": 3203340, "unexercisedValue": 15456209}, {"maxAge": 1, "name": "Ms. Sandra  Boenisch CPA, CGA", "age": 42, "title": "Principal Financial Officer & Treasurer", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 194358, "exercisedValue": 0, "unexercisedValue": 764381}, {"maxAge": 1, "name": "Dr. Walter E. Kaufmann M.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Clint  Tomlinson", "title": "VP of Corporate", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Adebayo  Laniyonu Ph.D.", "title": "Senior Vice President of Nonclinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edward R Hammond M.D., M.P.H., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kun  Jin Ph.D.", "title": "Head of Biostatistics", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Goldberger R.Ph.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Terrie  Kellmeyer Ph.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juan Carlos  Lopez-Talavera M.D., Ph.D.", "title": "Senior VP & Head of Research and Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 4, "compensationRisk": 8, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.74, "open": 11.2604, "dayLow": 10.95, "dayHigh": 12.46, "regularMarketPreviousClose": 10.74, "regularMarketOpen": 11.2604, "regularMarketDayLow": 10.95, "regularMarketDayHigh": 12.46, "beta": 0.604, "forwardPE": 2.3776906, "volume": 3382948, "regularMarketVolume": 3382948, "averageVolume": 1568572, "averageVolume10days": 3147950, "averageDailyVolume10Day": 3147950, "bid": 12.1, "ask": 12.23, "bidSize": 1400, "askSize": 700, "marketCap": 1030508352, "fiftyTwoWeekLow": 3.25, "fiftyTwoWeekHigh": 14.441, "fiftyDayAverage": 8.3252, "twoHundredDayAverage": 5.801925, "currency": "USD", "enterpriseValue": 593029312, "floatShares": 82205862, "sharesOutstanding": 84815504, "sharesShort": 19693094, "sharesShortPriorMonth": 18308959, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.2322, "heldPercentInsiders": 0.030480001, "heldPercentInstitutions": 0.32035, "shortRatio": 10.82, "shortPercentOfFloat": 0.23959999, "impliedSharesOutstanding": 84815504, "bookValue": 1.531, "priceToBook": 7.9359894, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -41528000, "trailingEps": -0.52, "forwardEps": -0.63, "lastSplitFactor": "1:4", "lastSplitDate": 1444176000, "52WeekChange": 0.7074722, "SandP52WeekChange": 0.25443196, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AVXL", "underlyingSymbol": "AVXL", "shortName": "Anavex Life Sciences Corp.", "longName": "Anavex Life Sciences Corp.", "firstTradeDateEpochUtc": 1154525400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a192134c-09ce-387b-bb62-3b271f6333ed", "messageBoardId": "finmb_13580387", "gmtOffSetMilliseconds": -18000000, "currentPrice": 12.15, "targetHighPrice": 46.0, "targetLowPrice": 15.0, "targetMeanPrice": 35.9725, "targetMedianPrice": 41.445, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 138756000, "totalCashPerShare": 1.636, "quickRatio": 11.951, "currentRatio": 12.041, "returnOnAssets": -0.20433001, "returnOnEquity": -0.30034, "freeCashflow": -19058068, "operatingCashflow": -30003000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]